International Publisher of Science, Technology and Medicine

 
 
Share this
 
 
 
Track Your Manuscript
 
 
 
 
Advances in Genetic Engineering & Biotechnology
Editor-in-chief: Cassandra Smith, PhD
Boston University, USA view all
ISSN: 2324-9021
Frequency: Quarterly
 
The Journal of Advances in Genetic Engineering & Biotechnology (AGEB) promotes rigorous research that makes a significant contribution in advancing knowledge for Genetic Engineering and Biotechnology. AGEB includes all major themes pertaining to Genetic Engineering and recombinant DNA technology.
 
Advances in Genetic Engineering & Biotechnology is a subscription based journal that provides a range of options to purchase our articles and also permits unlimited Internet Access to complete Journal content. It accepts research, review papers, online letters to the editors & brief comments on previously published articles or other relevant findings in SciTechnol. Articles submitted by authors are evaluated by a group of peer review experts in the field and ensures that the published articles are of high quality, reflect solid scholarship in their fields, and that the information they contain is accurate and reliable.
 
The Journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Advances in Genetic Engineering & Biotechnology or outside experts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.
 
Manuscripts can be submitted through Online or send as an e-mail attachment to the Editorial Office at editor.ageb@scitechnol.com or editor.ageb@scitechnol.org
 
Current Issue
Editors & Editorial Board Members  
Adv Genet Eng Biotechnol 2012, 1:1    
  PDF   
Cryopreservation: A Strategy Technique for Safe Preservation of Genetically Transformed Plant Materials   Editorial
Qiaochun Wang, Renrui Wang, Baiquan Li and Zhenhua Cui
Adv Genet Eng Biotechnol 2012, 1:1    doi: 10.4172/2324-9021.1000e101
 Preview

Cryopreservation: A Strategy Technique for Safe Preservation of Genetically Transformed Plant Materials

The world population now is 6.7 billion and is predicted to reach 9 billion by 2050. Such a rapid growing population has tremendously increased the challenge for food security. Obviously, it is impossible for traditional agriculture to ensure the food security, while plant biotechnology offers considerable potential to realize this goal. Commercial cultivation of genetically modified (GM) crops started in 1996. Since then, cultivation of GM crops has rapidly increased and the total cultivation areas of GM crops had reached 134 million ha by 2009.

|  Full Text |   PDF   
Mitochondrial DNA as a Marker for Genetic Diversity and Evolution   Editorial
Othman El-Mahdy Othman
Adv Genet Eng Biotechnol 2012, 1:1    doi: 10.4172/2324-9021.1000e102
 Preview

Mitochondrial DNA as a Marker for Genetic Diversity and Evolution

The formulation of the modern breed concept during mid-1800s has caused remarkable changes in the livestock sector: largescale production expanded and its application to breeding and husbandry practices led to the formation of well-defined breeds, exposed to intense anthropogenic selection. As a consequence, farmers progressively substituted the less productive, locally adapted, native breeds with highly productive cosmopolitan breeds and progressively abandoned marginal areas.

|  Full Text |   PDF   
Omics-Based CHO Cell Engineering Entrance into Post-Genomic Era   Editorial
Yeon-Gu Kim
Adv Genet Eng Biotechnol 2012, 1:1    doi: 10.4172/2324-9021.1000e103
 Preview

Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era

Chinese hamster ovary cells (CHO) cells have been the most commonly used mammalian host for the production of therapeutic proteins since the first therapeutic protein from recombinant mammalian cells, tissue plasminogen activator (tPA, Genentech, USA) synthesized in CHO cells, was approved for clinical use in 1987. Despite the availability of various mammalian cell lines (such as BHK, HEK-293, HeLa, NS0, and PerC6), nearly 70% of all recombinant protein therapeutics produced today are made in CHO cells.

|  Full Text |   PDF   
Epigenetics Interplay between DNA Methylation and Histone Modifications in Breast Cancer   Editorial
Siew Ching Ngai
Adv Genet Eng Biotechnol 2012, 1:1    doi: 10.4172/2324-9021.1000e104
 Preview

Epigenetics Interplay between DNA Methylation and Histone Modifications in Breast Cancer

Breast cancer is the most common cancer among the women worldwide. It accounts for 23% of total cancer cases and 14% of the cancer deaths. Breast cancer is a heterogeneous disease that results from the genetic and epigenetic events, including activation of oncogenes and inactivation of tumor suppressor genes.

|  Full Text |   PDF